ML Bio Solutions

On the heels of positive Phase III data for its cardiomyopathy drug, hub-and-spoke company BridgeBio Pharma, Inc. has another bit of good news with an agreement with the US Food and Drug Administrat

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com